ADMA Biologics (NASDAQ:ADMA - Get Free Report) had its price target increased by equities researchers at Raymond James from $18.00 to $25.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has a "strong-buy" rating on the biotechnology company's stock. Raymond James' price objective would indicate a potential upside of 6.43% from the company's previous close.
Several other equities analysts also recently commented on ADMA. HC Wainwright restated a "buy" rating and issued a $18.00 price target on shares of ADMA Biologics in a research note on Monday, October 14th. Cantor Fitzgerald reissued an "overweight" rating and issued a $20.00 price objective on shares of ADMA Biologics in a report on Friday, September 20th. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $19.25.
Check Out Our Latest Research Report on ADMA Biologics
ADMA traded up $3.77 on Friday, reaching $23.49. The company had a trading volume of 5,911,314 shares, compared to its average volume of 3,648,255. ADMA Biologics has a fifty-two week low of $3.60 and a fifty-two week high of $23.52. The company's fifty day moving average is $18.01 and its 200 day moving average is $13.73. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.80 and a current ratio of 6.87. The stock has a market cap of $5.48 billion, a P/E ratio of 167.79 and a beta of 0.64.
ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The biotechnology company reported $0.13 EPS for the quarter, beating analysts' consensus estimates of $0.08 by $0.05. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The firm had revenue of $107.20 million for the quarter, compared to analyst estimates of $86.44 million. During the same period in the prior year, the firm posted ($0.02) EPS. The company's revenue for the quarter was up 78.4% on a year-over-year basis. As a group, analysts predict that ADMA Biologics will post 0.49 earnings per share for the current fiscal year.
In other news, Director Lawrence P. Guiheen sold 9,000 shares of the business's stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $18.47, for a total value of $166,230.00. Following the completion of the transaction, the director now directly owns 153,941 shares in the company, valued at approximately $2,843,290.27. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director Lawrence P. Guiheen sold 9,000 shares of ADMA Biologics stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $18.47, for a total value of $166,230.00. Following the transaction, the director now directly owns 153,941 shares of the company's stock, valued at $2,843,290.27. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Adam S. Grossman sold 236,889 shares of the business's stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the transaction, the chief executive officer now owns 2,059,726 shares of the company's stock, valued at approximately $36,436,552.94. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 466,900 shares of company stock valued at $8,224,121. 3.70% of the stock is owned by corporate insiders.
Several large investors have recently bought and sold shares of the business. USA Financial Formulas lifted its holdings in shares of ADMA Biologics by 8.6% in the third quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company's stock worth $136,000 after acquiring an additional 539 shares during the last quarter. Vontobel Holding Ltd. lifted its stake in ADMA Biologics by 7.0% in the 3rd quarter. Vontobel Holding Ltd. now owns 13,643 shares of the biotechnology company's stock valued at $273,000 after purchasing an additional 888 shares during the last quarter. Hollencrest Capital Management acquired a new stake in ADMA Biologics in the third quarter valued at approximately $30,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of ADMA Biologics by 21.8% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,430 shares of the biotechnology company's stock worth $163,000 after buying an additional 1,509 shares during the last quarter. Finally, Chartwell Investment Partners LLC increased its holdings in shares of ADMA Biologics by 0.8% during the third quarter. Chartwell Investment Partners LLC now owns 249,779 shares of the biotechnology company's stock worth $4,993,000 after buying an additional 2,038 shares in the last quarter. 75.68% of the stock is owned by institutional investors and hedge funds.
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.